Diroximel fumarate in patients with relapsing–remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 studyB. Singer, Sibyl Wray, Ralf Gold et al.|Multiple Sclerosis Journal|2023Cited by 23
Thalamic atrophy and dysconnectivity are associated with cognitive impairment in a multi-center, clinical routine, real-word study of people with relapsing-remitting multiple sclerosisRobert Zivadinov, Ralph H. B. Benedict, Niels Bergsland et al.|NeuroImage Clinical|2024Cited by 13